Patrick Mehlen

Title: Patrick Mehlen: Innovator in Cancer Treatment

Introduction

Patrick Mehlen is a notable inventor based in Sérézin-de-la-Tour, France. He has made significant contributions to the field of cancer treatment through his innovative research and development of therapeutic strategies. His work focuses on the intersection of immunology and cancer biology, particularly in the context of targeting netrin-1.

Latest Patents

Patrick Mehlen holds a patent for a groundbreaking invention titled "Combined treatment with Netrin-1 interfering drug and immune checkpoint inhibitors drugs." This invention involves the combination of a compound that disrupts the interaction between netrin-1 and its receptors, known as a NTN1 neutralizing agent, with immune checkpoint inhibitors for cancer treatment. The composition may include an anti-netrin-1 antibody and an immune checkpoint inhibitor, which can be administered simultaneously, separately, or sequentially to patients.

Career Highlights

Throughout his career, Patrick Mehlen has worked with prominent organizations, including Netris Pharma and Université Claude Bernard—Lyon 1. His research has been pivotal in advancing the understanding of cancer therapies and improving treatment outcomes for patients.

Collaborations

Patrick has collaborated with esteemed colleagues such as Benjamin Ducarouge and David Goldschneider. These partnerships have fostered a collaborative environment that enhances the development of innovative cancer treatments.

Conclusion

Patrick Mehlen's contributions to cancer treatment through his patent and collaborative efforts highlight his role as a leading inventor in the field. His work continues to inspire advancements in therapeutic strategies for cancer patients.